Saw Palmetto (Serenoa repens)

Of 1,603 on-market saw palmetto (serenoa repens) products in the January 2026 DSLD dump, the median declared dose is 200 mg, and 52.1% list Saw palmetto berry/fruit extract (lipophilic: CO2, hexane or oil; usually standardized to fatty acids/sterols) as the primary form.

Form share

Of 1,477 products with an identifiable primary form, here is the share held by each form of Saw Palmetto (Serenoa repens) on the market today.

Form share over time

Entry-year breakdown of the top forms, 2012–2025.

Dose distribution

Deciles of declared dose per serving (mg), among 991 products with a disclosed amount.

• 18.1% of products fall below the fairy-dust threshold (64 mg, 20% of the studied low dose).
• 37.3% of products don't disclose an amount because Saw Palmetto (Serenoa repens) is declared inside a proprietary blend.

Where does your dose rank?

Enter a per-serving dose (mg) to see exactly how it compares to the 991 on-market saw palmetto (serenoa repens) products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.

Top brands

Search interest over time

How often people search for saw palmetto (serenoa repens) on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.

Or see this search directly on trends.google.com.

Forms explained

Reference values

• RDA (adult): not established — Not an essential nutrient; no RDA/AI exists.
• Tolerable Upper Intake Level (adult): not established — Not established. NCCIH (https://www.nccih.nih.gov/health/saw-palmetto, fetched) states saw palmetto is well tolerated, has been used safely in research studies for up to 3 years, lists mild and infrequent adverse effects (digestive symptoms, dizziness, headache), says it does not appear to affect PSA readings, and states it may be unsafe during pregnancy or breastfeeding. It gives no numeric upper limit.
• Studied clinical dose range: 320–960 mg
• Barry MJ et al. 2011 (CAMUS trial), JAMA 306(12):1344-1351, PMID 21954478 -- double- blind placebo-controlled RCT (n=369 men with BPH-attributed lower urinary tract symptoms), saw palmetto fruit extract at 320 mg/day (the "standard" dose), stepped to 640 then 960 mg/day at weeks 24 and 48; AUA symptom index change from baseline to 72 weeks was -2.20 with extract vs -2.99 with placebo, i.e. no benefit over placebo, at any dose, for any secondary outcome. Pooled evidence: Franco JV et al. 2023, Cochrane Database Syst Rev 6(6):CD001423, PMID 37345871 -- 27 studies/4,656 participants; Serenoa repens vs placebo gave little to no difference in urologic symptoms (high-certainty evidence) at 3-6 and 12-17 months.
• Note: Unit basis: mg of saw palmetto berry powder or extract as declared (the studied 320 mg/day is a standardized lipophilic extract; label rows often declare "% fatty acids" in raw_form instead, e.g. "Fatty Acids; Sterols"). The evidence above is a negative result for BPH symptoms, which is the main marketed use; it is recorded as studied dose, not as efficacy. Habib FK and Wyllie MG 2004 (Prostate Cancer Prostatic Dis 7(3):195-200, PMID 15289814) found marked brand-to-brand differences in fatty-acid and ester composition across 14 commercial extracts, so extract mass alone does not define the active content.